Pulmonary fibrosis model using micro-CT analyzable human PSC-derived alveolar organoids containing alveolar macrophage-like cells

利用微型CT可分析的人类多能干细胞来源的肺泡类器官(含有肺泡巨噬细胞样细胞)构建肺纤维化模型

阅读:5
作者:Seri Choi # ,Jiwoong Choi # ,Seongmin Cheon ,Jihong Song ,Seung-Yeon Kim ,Ji-Eun Kim ,Dae-Hwan Nam ,Gohar Manzar ,Su-Man Kim ,Hyung-Sik Kang ,Kee K Kim ,Sang Hoon Jeong ,Ju-Han Lee ,Eun-Kee Park ,Minseob Lee ,Hyang-Ae Lee ,Ki-Suk Kim ,Han-Jin Park ,Won Keun Oh ,Chungoo Park ,Chang Hyun Lee ,Eun-Mi Kim

Abstract

Human lung organoids (hLOs) are useful for disease modelling and drug screening. However, a lack of immune cells in hLOs limits the recapitulation of in vivo cellular physiology. Here, we generated hLOs containing alveolar macrophage (AMφ)-like cells derived from pluripotent stem cells (PSC). To bridge hLOs with advanced human lung high-resolution X-ray computed tomography (CT), we acquired quantitative micro-CT images. Three hLO types were observed during differentiation. Among them, alveolar hLOs highly expressed not only lung epithelial cell markers but also AMφ-specific markers. Furthermore, CD68+ AMφ-like cells were spatially organized on the luminal epithelial surface of alveolar hLOs. Bleomycin-treated alveolar hLOs showed upregulated expression of fibrosis-related markers and extracellular matrix deposits in the alveolar sacs. Alveolar hLOs also showed structural alterations such as excessive tissue fraction under bleomycin treatment. Therefore, we suggest that micro-CT analyzable PSC-derived alveolar hLOs are a promising in vitro model to predict lung toxicity manifestations, including fibrosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。